These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Albert BJ; Niu A; Ramani R; Marshall GR; Wender PA; Williams RM; Ratner L; Barnes AB; Kyei GB Sci Rep; 2017 Aug; 7(1):7456. PubMed ID: 28785069 [TBL] [Abstract][Full Text] [Related]
7. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors. Painter MM; Zaikos TD; Collins KL J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396 [TBL] [Abstract][Full Text] [Related]
8. The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal. Richard K; Schonhofer C; Giron LB; Rivera-Ortiz J; Read S; Kannan T; Kinloch NN; Shahid A; Feilcke R; Wappler S; Imming P; Harris M; Brumme ZL; Brockman MA; Mounzer K; Kossenkov AV; Abdel-Mohsen M; Andrae-Marobela K; Montaner LJ; Tietjen I J Biol Chem; 2020 Oct; 295(41):14084-14099. PubMed ID: 32788215 [TBL] [Abstract][Full Text] [Related]
9. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators. Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127 [TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921 [TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454 [TBL] [Abstract][Full Text] [Related]
12. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism. Díaz L; Martínez-Bonet M; Sánchez J; Fernández-Pineda A; Jiménez JL; Muñoz E; Moreno S; Álvarez S; Muñoz-Fernández MÁ Sci Rep; 2015 Jul; 5():12442. PubMed ID: 26199173 [TBL] [Abstract][Full Text] [Related]
13. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. Archin NM; Keedy KS; Espeseth A; Dang H; Hazuda DJ; Margolis DM AIDS; 2009 Sep; 23(14):1799-806. PubMed ID: 19590405 [TBL] [Abstract][Full Text] [Related]
14. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566 [TBL] [Abstract][Full Text] [Related]
15. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643 [TBL] [Abstract][Full Text] [Related]
16. A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway. Lu W; Yang C; Xu X; Chen C; Hou X; Fang H; Liu S Life Sci; 2021 Feb; 267():118427. PubMed ID: 32941894 [TBL] [Abstract][Full Text] [Related]
17. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat. De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142 [TBL] [Abstract][Full Text] [Related]
18. Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency. Schonhofer C; Yi J; Sciorillo A; Andrae-Marobela K; Cochrane A; Harris M; Brumme ZL; Brockman MA; Mounzer K; Hart C; Gyampoh K; Yuan Z; Montaner LJ; Tietjen I Biochem Pharmacol; 2021 Apr; 186():114462. PubMed ID: 33577894 [TBL] [Abstract][Full Text] [Related]
19. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022 [TBL] [Abstract][Full Text] [Related]
20. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. Huber K; Doyon G; Plaks J; Fyne E; Mellors JW; Sluis-Cremer N J Biol Chem; 2011 Jun; 286(25):22211-8. PubMed ID: 21531716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]